JP2023071729A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023071729A5 JP2023071729A5 JP2023020373A JP2023020373A JP2023071729A5 JP 2023071729 A5 JP2023071729 A5 JP 2023071729A5 JP 2023020373 A JP2023020373 A JP 2023020373A JP 2023020373 A JP2023020373 A JP 2023020373A JP 2023071729 A5 JP2023071729 A5 JP 2023071729A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- human
- population
- protein
- recombinant expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 20
- 239000013604 expression vector Substances 0.000 claims 7
- 238000003259 recombinant expression Methods 0.000 claims 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 2
- 230000006044 T cell activation Effects 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 claims 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 102000050320 human TNFRSF4 Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024118255A JP7739547B2 (ja) | 2017-06-30 | 2024-07-23 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
| JP2025146568A JP2025183273A (ja) | 2017-06-30 | 2025-09-03 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527556P | 2017-06-30 | 2017-06-30 | |
| US62/527,556 | 2017-06-30 | ||
| PCT/US2018/039917 WO2019006072A1 (en) | 2017-06-30 | 2018-06-28 | CHIMERIC ANTIGENIC RECEPTORS TO ANTIGEN OF MATURATION OF LYMPHOCYTES B WITH HUMAN DOMAINS |
| JP2019572798A JP7288405B2 (ja) | 2017-06-30 | 2018-06-28 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572798A Division JP7288405B2 (ja) | 2017-06-30 | 2018-06-28 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024118255A Division JP7739547B2 (ja) | 2017-06-30 | 2024-07-23 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023071729A JP2023071729A (ja) | 2023-05-23 |
| JP2023071729A5 true JP2023071729A5 (https=) | 2023-07-07 |
| JP7527419B2 JP7527419B2 (ja) | 2024-08-02 |
Family
ID=63350586
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572798A Active JP7288405B2 (ja) | 2017-06-30 | 2018-06-28 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
| JP2023020373A Active JP7527419B2 (ja) | 2017-06-30 | 2023-02-13 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
| JP2024118255A Active JP7739547B2 (ja) | 2017-06-30 | 2024-07-23 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
| JP2025146568A Pending JP2025183273A (ja) | 2017-06-30 | 2025-09-03 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572798A Active JP7288405B2 (ja) | 2017-06-30 | 2018-06-28 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024118255A Active JP7739547B2 (ja) | 2017-06-30 | 2024-07-23 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
| JP2025146568A Pending JP2025183273A (ja) | 2017-06-30 | 2025-09-03 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200138865A1 (https=) |
| EP (2) | EP3645568B1 (https=) |
| JP (4) | JP7288405B2 (https=) |
| KR (2) | KR102757010B1 (https=) |
| CN (1) | CN111094345B (https=) |
| AU (2) | AU2018291128B2 (https=) |
| ES (1) | ES2928296T3 (https=) |
| IL (1) | IL271597B2 (https=) |
| SG (1) | SG11201913175TA (https=) |
| WO (1) | WO2019006072A1 (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2766608C2 (ru) | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| HUE049514T2 (hu) | 2014-04-25 | 2020-09-28 | Bluebird Bio Inc | Javított eljárások adoptív sejtterápiák kialakítására |
| KR20250175345A (ko) | 2016-06-21 | 2025-12-16 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| PE20241349A1 (es) | 2016-09-14 | 2024-07-03 | Teneobio Inc | Anticuerpos de union a cd3 |
| WO2018085690A1 (en) | 2016-11-04 | 2018-05-11 | Bluebird Bio, Inc. | Anti-bcma car t cell compositions |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| CN110945026B (zh) | 2017-06-20 | 2024-03-19 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
| KR20250007003A (ko) | 2017-06-20 | 2025-01-13 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| US12415844B2 (en) * | 2017-12-20 | 2025-09-16 | Poseida Therapeutics, Inc. | BCMA specific VCAR compositions and methods for use |
| CN111683966B (zh) | 2017-12-22 | 2023-07-11 | 特尼奥生物股份有限公司 | 与cd22结合的重链抗体 |
| BR112020024074A2 (pt) | 2018-07-20 | 2021-02-17 | Teneobio, Inc. | anticorpos de cadeia pesada com ligação a cd19 |
| CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| WO2020206330A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| CR20210622A (es) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| CA3171906A1 (en) | 2020-03-16 | 2021-09-23 | University Of Southern California | Novel antigen binding domains and synthetic antigen receptors incorporating the same |
| IL297601A (en) | 2020-04-29 | 2022-12-01 | Teneobio Inc | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| TW202330622A (zh) | 2020-04-29 | 2023-08-01 | 美商泰尼歐生物公司 | 具有經修飾重鏈恆定區之多特異性重鏈抗體 |
| CN116472049A (zh) | 2020-06-30 | 2023-07-21 | 特尼奥生物股份有限公司 | 与bcma结合的多特异性抗体 |
| JP2024501971A (ja) | 2020-12-31 | 2024-01-17 | サナ バイオテクノロジー，インコーポレイテッド | Ｃａｒ－ｔ活性を調節するための方法及び組成物 |
| MX2023008081A (es) | 2021-01-11 | 2023-09-12 | Sana Biotechnology Inc | Uso de vectores virales dirigidos a cd8. |
| BR112023024231A2 (pt) | 2021-05-19 | 2024-01-30 | Sana Biotechnology Inc | Células t primárias rhd negativas hipoimunogênicas |
| US20240226164A1 (en) | 2021-05-27 | 2024-07-11 | Sana Biotechnology, Inc. | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
| WO2023274380A1 (zh) * | 2021-07-01 | 2023-01-05 | 宁波茂行生物医药科技有限公司 | 靶向IL13Rα2的通用型CAR-T细胞及其制备方法和应用 |
| KR20240046319A (ko) | 2021-07-14 | 2024-04-08 | 사나 바이오테크놀로지, 인크. | 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현 |
| EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| AU2022327174A1 (en) | 2021-08-11 | 2024-02-15 | Sana Biotechnology, Inc. | Inducible systems for altering gene expression in hypoimmunogenic cells |
| US20250313861A1 (en) | 2021-10-22 | 2025-10-09 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
| WO2023115041A1 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
| US20250059239A1 (en) | 2021-12-17 | 2025-02-20 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
| CN119072319A (zh) | 2021-12-23 | 2024-12-03 | 萨那生物技术股份有限公司 | 用于治疗自身免疫性疾病的嵌合抗原受体(car)t细胞及相关方法 |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4472646A1 (en) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4479416A1 (en) | 2022-02-17 | 2024-12-25 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| CN115851599B (zh) * | 2022-07-06 | 2026-03-17 | 上海优卡迪生物医药科技有限公司 | 一种用于治疗aml恶性肿瘤的cd38-car-t及其应用 |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| EP4698666A1 (en) | 2023-04-18 | 2026-02-25 | Sana Biotechnology, Inc. | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses |
| WO2024220598A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Lentiviral vectors with two or more genomes |
| WO2024220560A1 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Engineered protein g fusogens and related lipid particles and methods thereof |
| EP4716750A1 (en) | 2023-05-23 | 2026-04-01 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025006799A1 (en) | 2023-06-27 | 2025-01-02 | Capstan Therapeutics, Inc. | Extracorporeal and ex vivo engineering of select cell populations from peripheral blood |
| WO2025043172A1 (en) | 2023-08-23 | 2025-02-27 | Sana Biotechnology, Inc. | Modified cd47 proteins and their uses |
| WO2025054202A1 (en) | 2023-09-05 | 2025-03-13 | Sana Biotechnology, Inc. | Method of screening a sample comprising a transgene with a unique barcode |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250144234A1 (en) | 2023-11-02 | 2025-05-08 | Capstan Therapeutics Inc. | RNA for In vivo Transfection with Increased Expression |
| GB202317065D0 (en) | 2023-11-07 | 2023-12-20 | Coding Bio Ltd | BCMA binding molecules |
| US20250332281A2 (en) | 2023-12-15 | 2025-10-30 | Capstan Therapeutics, Inc. | Humanized anti-cd8 antibodies and uses thereof |
| WO2025151838A1 (en) | 2024-01-12 | 2025-07-17 | Sana Biotechnology, Inc. | Safety switches to control in vitro and in vivo proliferation of cell therapy products |
| US20250242018A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025160324A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
| WO2026072709A1 (en) | 2024-09-25 | 2026-04-02 | Orna Therapeutics, Inc. | Chimeric antigen receptors targeting bcma |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2766608C2 (ru) * | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| ES2857226T3 (es) * | 2014-03-15 | 2021-09-28 | Novartis Ag | Receptor de antígeno quimérico regulable |
| PE20170441A1 (es) | 2014-06-06 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| ES2878449T3 (es) | 2014-07-24 | 2021-11-18 | 2Seventy Bio Inc | Receptores antigénicos quiméricos de BCMA |
| WO2018028647A1 (en) * | 2016-08-10 | 2018-02-15 | Legend Biotech Usa Inc. | Chimeric antigen receptors targeting bcma and methods of use thereof |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| KR20250007003A (ko) | 2017-06-20 | 2025-01-13 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| CN110945026B (zh) * | 2017-06-20 | 2024-03-19 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
-
2018
- 2018-06-28 ES ES18759189T patent/ES2928296T3/es active Active
- 2018-06-28 US US16/626,991 patent/US20200138865A1/en not_active Abandoned
- 2018-06-28 SG SG11201913175TA patent/SG11201913175TA/en unknown
- 2018-06-28 KR KR1020207002752A patent/KR102757010B1/ko active Active
- 2018-06-28 AU AU2018291128A patent/AU2018291128B2/en active Active
- 2018-06-28 EP EP18759189.6A patent/EP3645568B1/en active Active
- 2018-06-28 IL IL271597A patent/IL271597B2/en unknown
- 2018-06-28 JP JP2019572798A patent/JP7288405B2/ja active Active
- 2018-06-28 CN CN201880044208.XA patent/CN111094345B/zh active Active
- 2018-06-28 KR KR1020257001390A patent/KR20250012203A/ko active Pending
- 2018-06-28 WO PCT/US2018/039917 patent/WO2019006072A1/en not_active Ceased
- 2018-06-28 EP EP22187063.7A patent/EP4159762A1/en active Pending
-
2023
- 2023-02-13 JP JP2023020373A patent/JP7527419B2/ja active Active
- 2023-11-30 US US18/524,799 patent/US12570717B2/en active Active
-
2024
- 2024-07-23 JP JP2024118255A patent/JP7739547B2/ja active Active
- 2024-10-29 AU AU2024227725A patent/AU2024227725A1/en active Pending
-
2025
- 2025-09-03 JP JP2025146568A patent/JP2025183273A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023071729A5 (https=) | ||
| JP2020529841A5 (https=) | ||
| JP6675417B2 (ja) | キメラ抗原受容体 | |
| JP2022523961A5 (https=) | ||
| ES2843599T3 (es) | Receptor de antígeno quimérico | |
| JP2022109953A5 (https=) | ||
| JP2023527049A5 (https=) | ||
| JP2021191265A5 (https=) | ||
| GB2611448A (en) | Polypeptide useful in adoptive cell therapy | |
| JP2023139070A5 (https=) | ||
| JP2019500848A5 (https=) | ||
| JP2023524054A5 (https=) | ||
| US20240101616A1 (en) | Dap10/12 based cars adapted for rush | |
| JP2019514361A5 (https=) | ||
| RU2022103665A (ru) | Химерные конструкции антитело/t-клеточный рецептор и их применения | |
| JP2020513754A5 (https=) | ||
| JP2019535262A5 (https=) | ||
| JPH05501062A (ja) | Ｈｉｖ―１のウイルス性コンプレックス抗原に結合する組換え蛋白質 | |
| Romano et al. | Molecular cloning and characterization of CD4 in an aquatic mammal, the white whale Delphinapterus leucas | |
| JP2022545815A5 (https=) | ||
| JP2019530441A5 (https=) | ||
| JP2024544559A5 (https=) | ||
| JP2023524132A5 (https=) | ||
| WO2020253879A1 (zh) | 一种双特异性嵌合抗原受体 | |
| WO1997004109A1 (fr) | PROTEINES HETERO-MULTIMERIQUES RECOMBINANTES DU TYPE α - β C4BP |